Form 4 Subramanian Kala

4 - Statement of changes in beneficial ownership of securities

Published: 2017-06-19 16:05:33
Submitted: 2017-06-19
Period Ending In: 2017-06-15
doc4.html FORM 4 SUBMISSION


>

SEC FORM 4

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Subramanian Kala

(Last) (First) (Middle)
C/O CRISPR THERAPEUTICS, INC.
610 MAIN STREET

(Street)
CAMBRIDGE MA 02139

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CRISPR Therapeutics AG [ CRSP ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
See Remarks
3. Date of Earliest Transaction (Month/Day/Year)
06/15/2017
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Options (Right to Buy) $14.43 06/15/2017 A 85,000 (1) 06/15/2027 Common Shares 85,000 $0.00 85,000 D
Explanation of Responses:
1. This option was granted on June 15, 2017 with respect to 85,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning on July 15, 2017.
Remarks:
Senior Vice President, Strategic Development and Operations
/s/ Kala Subramanian 06/19/2017
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
1
doc4.xml FORM 4 SUBMISSION
Schema Version:
X0306
Document Type:
4
Period Of Report:
2017-06-15
Not Subject To Section16:
0

Issuer

Issuer Cik
0001674416
Issuer Name
CRISPR Therapeutics AG
Issuer Trading Symbol
CRSP

Reporting Owner

Reporting Owner Id

Rpt Owner Cik
0001682026
Rpt Owner Name
Subramanian Kala

Reporting Owner Address

Rpt Owner Street1
C/O CRISPR THERAPEUTICS, INC.
Rpt Owner Street2
610 MAIN STREET
Rpt Owner City
CAMBRIDGE
Rpt Owner State
MA
Rpt Owner Zip Code
02139

Reporting Owner Relationship

Is Director
0
Is Officer
1
Is Ten Percent Owner
0
Is Other
0
Officer Title
See Remarks

Derivative Transaction

Security Title
Stock Options (Right to Buy)
Conversion Or Exercise Price
14.43
Transaction Date
2017-06-15

Transaction Coding

Transaction Form Type
4
Transaction Code
A
Equity Swap Involved
0

Transaction Amounts

Transaction Shares
85000
Transaction Price Per Share
0.00
Transaction Acquired Disposed Code
A
@attributes Id
F1
Expiration Date
2027-06-15

Underlying Security

Underlying Security Title
Common Shares
Underlying Security Shares
85000
Shares Owned Following Transaction
85000
Direct Or Indirect Ownership
D
Footnotes Footnote
This option was granted on June 15, 2017 with respect to 85,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning on July 15, 2017.
Remarks:
Senior Vice President, Strategic Development and Operations

Owner Signature

Signature Name
/s/ Kala Subramanian
Signature Date
2017-06-19
attachment1.htm EX-24 DOCUMENT


> ENT> EX-24 2 attachment1.htm EX-24 DOCUMENT
                               POWER OF ATTORNEY

        Know all by these presents, that the undersigned hereby constitutes and
appoints each of Marc Becker, Michael Esposito and Robert E. Puopolo, signing
singly, the undersigned's true and lawful attorney-in-fact to:

          (1)   execute for and on behalf of the undersigned, in the
                undersigned's capacity as an officer and/or director of CRISPR
                Therapeutics AG (the "Company"), (i) Form ID, including any
                attached documents, to effect the assignment of codes to the
                undersigned to be used in the transmission of information to the
                United States Securities and Exchange Commission using the EDGAR
                System, and (ii) Forms 3, 4 and 5 and amendments thereto in
                accordance with Section 16(a) of the Securities Exchange Act of
                1934, as amended, and the rules thereunder;

          (2)   do and perform any and all acts for and on behalf of the
                undersigned which may be necessary or desirable to complete and
                execute any such Form 3, 4 or 5 and amendments thereto and
                timely file such form with the United States Securities and
                Exchange Commission and any stock exchange or similar authority;
                and

          (3)   take any other action of any type whatsoever in connection with
                the foregoing which, in the opinion of such attorney-in-fact,
                may be of benefit to, in the best interest of, or legally
                required by, the undersigned, it being understood that the
                documents executed by such attorney-in-fact on behalf of the
                undersigned pursuant to this Power of Attorney shall be in such
                form and shall contain such terms and conditions as such
                attorney-in-fact may approve in such attorney-in-fact's
                discretion.

        The undersigned hereby grants to each such attorney-in-fact full power
and authority to do and perform any and every act and thing whatsoever
requisite, necessary, or proper to be done in the exercise of any of the rights
and powers herein granted, as fully to all intents and purposes as the
undersigned might or could do if personally present, with full power of
substitution or revocation, hereby ratifying and confirming all that such
attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall
lawfully do or cause to be done by virtue of this Power of Attorney and the
rights and powers herein granted. The undersigned acknowledges that the
foregoing attorneys-in-fact, in serving in such capacity at the request of the
undersigned, are not assuming, nor is the Company assuming, any of the
undersigned's responsibilities to comply with Section 16 of the Securities
Exchange Act of 1934, as amended. The undersigned hereby agrees to indemnify the
attorney-in-fact and the Company from and against any demand, damage, loss, cost
or expense arising from any false or misleading information provided by the
undersigned to the attorney-in-fact.

        This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.  This Power of Attorney may be filed with the
United States Securities and Exchange Commission as a confirming statement of
the authority granted herein. This Power of Attorney supersedes any prior power
of attorney in connection with the undersigned's capacity as an officer and/or
director of the Company.  This Power of Attorney shall expire as to any
individual attorney-in-fact if such attorney-in-fact ceases to be an executive
officer of, or legal counsel to the Company.

        IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed as of July 18, 2016.


                                                      /s/ Kala Subramanian
                                                --------------------------------
                                                            Signature


                                                         Kala Subramanian
                                                --------------------------------
                                                            Print Name


Additional Files
FileSequenceDescriptionTypeSize
0000899243-17-016671.txt   Complete submission text file   10133
$CRSP

© 2019 SEC.report
SEC CFR Title 17 of the Code of Federal Regulations.